Trial Profile
A Multicentre, Open-label, Single Ascending Dose Phase 1 Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS Tablets in Pediatric Subjects From 5 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Jan 2022
Price :
$35
*
At a glance
- Drugs Mirabegron (Primary)
- Indications Detrusor instability; Overactive bladder
- Focus Pharmacokinetics
- Sponsors Astellas Pharma
- 02 Oct 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 23 Jul 2014 New trial record